Cyclovirobuxine inhibits ferroptosis to mitigate Alzheimer disease in glutamate-induced SH-SY5Y cell: the role of the liquid-liquid phase separation of FTH1. (PubMed, Mol Pharmacol) - Jun 24, 2025 - "Cyc treatment conferred resistance to ferroptosis in erastin-stimulated SH-SY5Y cells, wherein the Nrf2 signaling pathway and FTH1 protein play crucial roles. The collective findings presented here underscore the protective mechanism of action of Cyc in AD and emphasize its potential as a therapeutic agent for AD treatment. SIGNIFICANCE STATEMENT: It reveals at the cellular level the mechanism by which cyclovirobuxine improves Alzheimer disease through the inhibition of ferroptosis, providing a novel approach and strategy for the treatment of patients with Alzheimer disease."
Journal • Alzheimer's Disease • CNS Disorders
|
|
Baohong Li; Fuwei Wang; Jiantao Lin; Jikun Du; Li Li; Lihua Xie; Nan Zheng; Qiang Sun; Qiong Zhou; Zihao Chen; Ziwen Chen
|